Dr. Reddy's Laboratories Ltd. closed 8.38% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Citi believes that market expectations for the GLP-1 opportunity in Canada may be too optimistic, based on its latest deep ...

Dr. Reddy's Laboratories Ltd. 500124 shares slid 1.47% to 1,321.20 Indian rupees Thursday, on what proved to be an all-around ...

Dr. Reddy's Laboratories, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1326.4.The stock has experienced fluctuations today ...

Shares of Dr Reddy's Laboratories decreased by 2 per cent to Rs 1,317 in morning trading, following Citi Research's decision ...

Citi expressed caution on the growth outlook, particularly around the Canadian GLP-1 market and the highly anticipated launch ...

The scrip traded higher than the 5-day, 10-, 20-, 30-, 50-, 100-, 150-day and 200-day simple moving averages (SMAs).

Ahmedabad: Intas Pharma has announced the appointment of Rambabu Ogirala as Associate Vice President - Manufacturing ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...